[go: up one dir, main page]

BRPI0917819B8 - compostos derivados poliméricos de benzil carbonato, conjugado de droga, formulação farmacêutica, e, uso de um conjugado - Google Patents

compostos derivados poliméricos de benzil carbonato, conjugado de droga, formulação farmacêutica, e, uso de um conjugado

Info

Publication number
BRPI0917819B8
BRPI0917819B8 BRPI0917819A BRPI0917819A BRPI0917819B8 BR PI0917819 B8 BRPI0917819 B8 BR PI0917819B8 BR PI0917819 A BRPI0917819 A BR PI0917819A BR PI0917819 A BRPI0917819 A BR PI0917819A BR PI0917819 B8 BRPI0917819 B8 BR PI0917819B8
Authority
BR
Brazil
Prior art keywords
conjugate
pharmaceutical formulation
drug
derivative compounds
carbonate derivative
Prior art date
Application number
BRPI0917819A
Other languages
English (en)
Inventor
Ambroise Arounaguiry
Melnick Bennett
Quinn Catherine
Jiang Cong
Yang Guohan
Li Jie
r brown Larry
Saunders Paul
That Hai Ton
Original Assignee
Baxalta GmbH
Baxalta Inc
Baxter Healthcare Sa
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Inc, Baxter Healthcare Sa, Baxter Int filed Critical Baxalta GmbH
Publication of BRPI0917819A2 publication Critical patent/BRPI0917819A2/pt
Publication of BRPI0917819B1 publication Critical patent/BRPI0917819B1/pt
Publication of BRPI0917819B8 publication Critical patent/BRPI0917819B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polyethers (AREA)
  • Polyesters Or Polycarbonates (AREA)

Abstract

composto, conjugado de droga, formulação farmacêutica, e, uso de um conjugado a presente invenção refere-se a derivados poliméricos, que podem ser conjugados a uma droga contendo amino para melhorar suas propriedades in vivo. o derivado polimérico pode subsequentemente ser liberado para produzir a droga em uma forma original. métodos de preparo e uso destes derivados poliméricos e conjugados de droga são descritos.
BRPI0917819A 2008-08-22 2009-08-21 compostos derivados poliméricos de benzil carbonato, conjugado de droga, formulação farmacêutica, e, uso de um conjugado BRPI0917819B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18975108P 2008-08-22 2008-08-22
US61/189751 2008-08-22
PCT/US2009/054595 WO2010022320A2 (en) 2008-08-22 2009-08-21 Polymeric benzyl carbonate-derivatives

Publications (3)

Publication Number Publication Date
BRPI0917819A2 BRPI0917819A2 (pt) 2015-11-24
BRPI0917819B1 BRPI0917819B1 (pt) 2020-11-10
BRPI0917819B8 true BRPI0917819B8 (pt) 2021-05-25

Family

ID=41531695

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917819A BRPI0917819B8 (pt) 2008-08-22 2009-08-21 compostos derivados poliméricos de benzil carbonato, conjugado de droga, formulação farmacêutica, e, uso de um conjugado

Country Status (12)

Country Link
US (2) US8653131B2 (pt)
EP (1) EP2328619B1 (pt)
JP (1) JP5731385B2 (pt)
KR (1) KR101660059B1 (pt)
AU (1) AU2009282747B2 (pt)
BR (1) BRPI0917819B8 (pt)
CA (1) CA2731184C (pt)
DK (1) DK2328619T3 (pt)
ES (1) ES2617868T3 (pt)
MX (1) MX2011001887A (pt)
NZ (1) NZ591045A (pt)
WO (1) WO2010022320A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993614B2 (en) 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
US11319408B2 (en) 2017-03-30 2022-05-03 Nof Corporation Hydrophilic polymer derivative having self-immolative acetal linker and conjugate using same
KR20220039729A (ko) * 2019-07-30 2022-03-29 마츠모토 파인케미칼 가부시키가이샤 규소이소시아네이트 화합물 함유 조성물 및 그 제조 방법

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3960871A (en) * 1971-12-27 1976-06-01 Sharps Associates Esters of thienobenzopyrans and thiopyranobenzopyrans
US3991194A (en) * 1971-12-27 1976-11-09 Sharps Associates Heterocyclic esters of benzopyranopyridines
US4042694A (en) * 1972-12-04 1977-08-16 Sharps Associates Novel heterocyclic esters of benzopyranopyridines
US4081449A (en) * 1973-04-05 1978-03-28 Abbott Laboratories Heterocyclic esters of alkylphenyl benzopyranopyridines
US4025630A (en) * 1973-09-19 1977-05-24 Abbott Laboratories Anesthesia methods using benzopyrans and esters thereof as pre-anesthesia medication
US3972880A (en) * 1974-03-05 1976-08-03 Sharps Associates Morpholine containing esters of thienobenzopyrans and thiopyranobenzopyrans
US4105776A (en) * 1976-06-21 1978-08-08 E. R. Squibb & Sons, Inc. Proline derivatives and related compounds
CA1102337A (en) 1976-02-13 1981-06-02 Miguel A. Ondetti Proline derivatives and related compounds
CA1103257A (en) 1976-02-13 1981-06-16 Miguel A. Ondetti Proline derivatives and related compounds
CA1103256A (en) 1976-02-13 1981-06-16 Miguel A. Ondetti Proline derivatives and related compounds
AU509899B2 (en) 1976-02-13 1980-05-29 E.R. Squibb & Sons, Inc. Proline derivatives and related compounds
CA1103255A (en) 1976-02-13 1981-06-16 Miguel A. Ondetti Proline derivatives and related compounds
US4046889A (en) * 1976-02-13 1977-09-06 E. R. Squibb & Sons, Inc. Azetidine-2-carboxylic acid derivatives
GB1584421A (en) 1976-05-10 1981-02-11 Hoffmann La Roche Process for the manufacture of tertiary optically active aliphatic compounds
MTP837B (en) * 1977-11-07 1979-10-22 Hoffman La Roche And Co Aktien Derivatives 2 finino-imidazolidire
JPS57192323A (en) 1981-05-18 1982-11-26 Nisshin Flour Milling Co Ltd Isoprenyl ether derivative
US4439364A (en) * 1982-09-01 1984-03-27 E. I. Du Pont De Nemours & Company Process for preparing antihypertensive 1-substituted cyclic lactam-2-carboxylic acids and their derivatives
AU600992B2 (en) * 1986-10-28 1990-08-30 Smith Kline & French Laboratories Limited Tetrahydroisoquinolin-2-yl derivatives of carboxylic acids
US4788206A (en) * 1987-07-10 1988-11-29 Hoffmann-La Roche Inc. Pentadieneamides
US4916145A (en) * 1987-07-10 1990-04-10 Hoffmann-La Roche Inc. Substituted n-[(pyridyl)alkyl]aryl-carboxamide
US4927826A (en) * 1987-07-10 1990-05-22 Hoffman-La Roche Inc. Cycloproylpropenamides useful as platelet activing factor (PAF) antagonists
NZ225307A (en) 1987-07-10 1991-06-25 Hoffmann La Roche Heterocyclic containing alkene derivatives and pharmaceutical compositions
US4927838A (en) * 1987-07-10 1990-05-22 Hoffman-La Roche Inc. Pyridine compounds which are useful in treating a disease state characterized by an excess of platelet activating factors
US4975438A (en) * 1987-07-10 1990-12-04 Hoffmann-La Roche Inc. Pentadieneamide compounds which have useful activity of treating a disease characterized by an excess of platelet activating factor
US4786646A (en) * 1987-07-10 1988-11-22 Hoffmann-La Roche Inc. Cyclopropylpropenamides
US5086052A (en) * 1987-07-17 1992-02-04 Abbott Laboratories Substituted 1,4,5,6-tetrahydro-2H-pyridazin-3-one and -3-thione compounds having lipoxygenase inhibitory activity
US4970210A (en) * 1987-07-17 1990-11-13 Abbott Laboratories Triazinone lipoxygenase compounds
DE3734751A1 (de) 1987-10-14 1989-05-03 Basf Ag Zwischenprodukte und verfahren fuer die herstellung von sexualpheromonen von miniermotten
DE3821540A1 (de) * 1988-06-25 1989-12-28 Boehringer Mannheim Gmbh Neue sulfonamide, verfahren zu ihrer herstellung sowie solche sulfonamide enthaltende arzneimittel
SE8900685D0 (sv) 1989-02-28 1989-02-28 Astra Ab New compounds
DE3925256A1 (de) 1989-07-29 1991-01-31 Basf Ag Substituierte 3-oxypropionsaeure-tert.-butylester
US5204463A (en) * 1989-08-10 1993-04-20 Glaxo Inc. Substituted methoxyphenyl-4,5 dihydro-3(2H)-pridazinones having cardiotonic and beta blocking activities
US5096904A (en) * 1989-09-01 1992-03-17 Glaxo Inc. Pyridazinones having cardiotonic and beta blocking activities
US5053338A (en) * 1989-09-01 1991-10-01 Glaxo Inc. Kinetic resolution of pyridazinones using lipase
JP2648584B2 (ja) 1990-02-16 1997-09-03 株式会社ディ・ディ・エス研究所 グリコシル−蛋白誘導体
JP2791001B2 (ja) 1990-02-16 1998-08-27 株式会社ディ・ディ・エス研究所 グリコシル−蛋白誘導体
JPH085914B2 (ja) 1990-02-16 1996-01-24 株式会社ディ・ディ・エス研究所 グリコシル−蛋白誘導体
JP2589435B2 (ja) 1991-09-17 1997-03-12 株式会社ディ・ディ・エス研究所 糖修飾ポリリジン誘導体
CA2091876A1 (en) * 1992-03-18 1993-09-19 Akio Miyake Imidazopyridazines, their production and use
GB9600344D0 (en) * 1996-01-09 1996-03-13 Lilly Co Eli Benzimidzolyl neuropeptide y receptor antagonists
JP2000501107A (ja) 1996-01-09 2000-02-02 イーライ・リリー・アンド・カンパニー ベンズイミダゾリル神経ペプチドｙ受容体アンタゴニスト
US6214966B1 (en) * 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
CA2287993A1 (en) 1997-04-30 1998-11-05 Mary George Johnson Antithrombotic agents
JP2001523255A (ja) 1997-04-30 2001-11-20 イーライ・リリー・アンド・カンパニー 抗血栓剤
US6284756B1 (en) * 1998-04-30 2001-09-04 Eli Lilly And Company Antithrombotic agents
JP4211099B2 (ja) 1998-11-09 2009-01-21 三菱化学株式会社 透明導電性積層シートの製造方法
US6713471B1 (en) * 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
AU781839B2 (en) * 1999-12-22 2005-06-16 Nektar Therapeutics Sterically hindered derivatives of water soluble polymers
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
BR0114619A (pt) * 2000-10-11 2005-12-13 Esperion Therapeutics Inc Composto, composição farmacêutica, métodos para tratar ou prevenir uma doença cardiovascular, uma dislipidemia, uma dislipoproteinemia, um distúrbio do metabolismo da glicose, trombótico e associado com o receptor ativado do proliferador de peroxissoma, a doença de alzheimer, a sìndrome x ou sìndrome metabólica, a septicemia, a obesidade, pancreatite, a hipertensão, doença renal, câncer, a inflamação e a impotência, em um paciente e para reduzir o teor de gordura da carne em animal de criação e de colesterol de ovos de aves domésticas
EP1235294A3 (en) * 2001-02-22 2005-06-22 Fuji Photo Film Co., Ltd. Electrolyte composition, method for producing the same and non-aqueous electrolyte secondary cell
US20050020694A1 (en) * 2001-10-11 2005-01-27 Dasseux Jean-Louis Henri Sulfide and disulfide compounds and compositions for cholesterol management and related uses
AU2003253890A1 (en) * 2002-07-12 2004-02-02 Biomarin Pharmaceutical Inc. The use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates
CA2500582A1 (en) * 2002-10-04 2004-04-22 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
ATE485331T1 (de) 2003-01-06 2010-11-15 Nektar Therapeutics Thiolselektive wasserlösliche polymerderivate
CA2514363A1 (en) * 2003-02-12 2004-08-26 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
HUE058897T2 (hu) * 2003-02-26 2022-09-28 Nektar Therapeutics Polimer VIII-as faktor egység konjugátumok
US7332164B2 (en) * 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
CA2843439A1 (en) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd Reversible pegylated drugs
AU2003902860A0 (en) * 2003-06-06 2003-06-26 Daicel Chemical Industries, Ltd Benzimidazole compounds
US7345190B2 (en) * 2003-11-12 2008-03-18 Ssv Therapeutics, Inc. Carnitine conjugates as dual prodrugs and uses thereof
AU2003300439A1 (en) 2003-12-24 2005-08-03 Esperion Therapeutics, Inc. Sulfide and disulfide compounds and compositions for cholesterol management and related uses
MY139887A (en) 2004-04-02 2009-11-30 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same.
AR048528A1 (es) 2004-04-07 2006-05-03 Millennium Pharm Inc Compuestos derivados de quinolina como antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias y composiciones farmacéuticas que los contienen.
FR2875805B1 (fr) * 2004-09-27 2006-12-29 Genfit S A Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations
US20080207505A1 (en) * 2005-01-12 2008-08-28 James Kenneth D Bna Conjugates and Methods of Use
CN100381420C (zh) 2005-03-23 2008-04-16 于勇海 一种n-乙酰基半胱氨酸衍生物与应用
US20090270655A1 (en) 2005-03-28 2009-10-29 Howard Lam-Ho Fong Conversion of Alkylhalides Into Alcohol Alkoxylates
WO2006104883A1 (en) 2005-03-28 2006-10-05 Shell Internationale Research Maatschappij B.V. Formation of heteroatom containing derivatives of paraffins
JP2006327984A (ja) 2005-05-26 2006-12-07 Fujifilm Holdings Corp ヘテロ二官能性オリゴエチレングリコールの合成方法及びこれを用いたバイオセンサーの製造方法
RS53968B1 (sr) 2005-06-16 2015-08-31 Nektar Therapeutics Konjugati koji imaju spojnicu koja može da se razgradi i polimerni reagensi koji su korisni za pripremu takvih konjugata
EP1991528A2 (en) 2006-01-18 2008-11-19 Siena Biotech S.p.A. Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
JP4975353B2 (ja) 2006-04-07 2012-07-11 ジェイカムアグリ株式会社 被覆粒状植物活性物質
WO2008012895A1 (en) 2006-07-27 2008-01-31 Mitsubishi Electric Corporation Elevator device
WO2008034122A2 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
JP5702066B2 (ja) * 2006-12-27 2015-04-15 ネクター セラピューティクス 解離可能な連結を有するフォンウィルブランド因子および第ｖｉｉｉ因子のポリマー共役体
CL2008000119A1 (es) 2007-01-16 2008-05-16 Wyeth Corp Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
AU2008240773B2 (en) 2007-04-19 2013-10-03 Glaxo Group Limited Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists
WO2009011285A1 (ja) 2007-07-13 2009-01-22 Taisho Pharmaceutical Co., Ltd. ヘテロアリールベンゼン化合物
CN101965195A (zh) 2008-03-05 2011-02-02 巴克斯特国际公司 用于药物投送的组合物和方法
JP5222187B2 (ja) 2009-03-12 2013-06-26 株式会社クボタ 有孔ブロックおよび有孔ブロックを備えた集水設備の施工方法
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery

Also Published As

Publication number Publication date
CA2731184C (en) 2017-03-21
DK2328619T3 (en) 2017-03-13
WO2010022320A2 (en) 2010-02-25
US8653131B2 (en) 2014-02-18
US20100048483A1 (en) 2010-02-25
KR20110055681A (ko) 2011-05-25
CA2731184A1 (en) 2010-02-25
JP5731385B2 (ja) 2015-06-10
NZ591045A (en) 2013-01-25
MX2011001887A (es) 2011-04-04
JP2012500804A (ja) 2012-01-12
US8962549B2 (en) 2015-02-24
BRPI0917819A2 (pt) 2015-11-24
AU2009282747B2 (en) 2015-04-02
AU2009282747A1 (en) 2010-02-25
WO2010022320A3 (en) 2010-08-19
US20140128445A1 (en) 2014-05-08
KR101660059B1 (ko) 2016-09-26
BRPI0917819B1 (pt) 2020-11-10
EP2328619B1 (en) 2016-12-07
ES2617868T3 (es) 2017-06-20
EP2328619A2 (en) 2011-06-08

Similar Documents

Publication Publication Date Title
CY1125300T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν οξειδιο-υδροξειδιο του σιδηρου
CY1121860T1 (el) Συνθετικα ενδιαμεσα για την παρασκευη συζευγματων ολιγοσακχαριτη-πρωτεϊνης
BRPI0910746B8 (pt) agente de reticulação, conjugado de agente de ligação celular-fármaco, seu uso, composto e composição farmacêutica
BRPI0905733A2 (pt) "composição, formulação farmacêutica, método para tratamento de câncer positivo para her2 e método pára a produção de uma composição farmacêutica"
ECSP13011139A (es) Anticuerpos contra la angiopoyetina 2 humana
BRPI0916877A2 (pt) composição farmacêutica e administração da mesma
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
WO2009140423A3 (en) Targeted polymer bioconjugates
BR112013007577A2 (pt) conjugado, composição farmacêutica, molécula de conjugação com amatoxina e método para a síntese de um conjugado
CL2007001648A1 (es) Compuesto derivado de leptomicina; conjugado que comprende agente de unión a células unido a uno o mas de dichos derivados; composiciones farmacéuticas que comprenden dicho derivado o conjugado; util en el tratamiento del cancer; proceso de preparacion de un compuesto o de un conjugado de un derivado de leptomicina.
IL244812A0 (en) 6-ethyl, 23-methyl-cholic acid, its conjugates with glycine and taurine and pharmaceutical preparations containing them
WO2009133352A3 (en) Lipid composition
SV2009003335A (es) Formulaciones para el cancer
MX391454B (es) Compuesto de engarce-fármaco para conjugación a una unidad de ligando.
NI201200038A (es) Conjugados de niacina y ácidos grasos y sus usos
UY30319A1 (es) Formulaciones de inhibidores de dpp iv
BRPI0915284A2 (pt) Composição famacêutica oral, método para tratar uma infecção fúngica e para tratar câncer em um mamífero, e, formulação de liberação prolongada oral
BRPI0908596A2 (pt) formulação e composição farmacêutica de liberação prolongada
CL2010001422A1 (es) Uso de dronedarona para la preparacion de un medicamento util en la prevencion de la fibrilacion/aleteo auricular permanente
BR112012003283A2 (pt) sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente.
EP2386553A4 (en) BENZIMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITIONS AND THEIR USE
BRPI0917502A2 (pt) composição farmacêtica, e, métodos para usar um ácido orgânico ou um antioxidante, para evitar a descoloração causada quando ácido tranemaxâmico e ácido ascórbico são incorporados em uma mesma composição, e para produzir uma preparação farmacêutica sólida para administração oral
BRPI0617294B8 (pt) composição farmacêutica em gel hidroalcóolico e uso de testosterona
WO2008081829A1 (ja) 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ
CY1119315T1 (el) Στερεες μορφες που περιεχουν μελοξικαμη με βελτιωμενη στοματικη γευση και η διαδικασια για τηn προετοιμασια τους

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BAXALTA GMBH (CH) , BAXALTA INCORPORATED (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/405 (2006.01), A61K 47/60 (2017.01), A61P

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/08/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: EXTINTA A PATENTE, NOS TERMOS DO ARTIGO 86, DA LPI, E ARTIGO 14 DA PORTARIA 52/2023, REFERENTE AO NAO RECOLHIMENTO DA 16A RETRIBUICAO ANUAL (VIDE PARECER).

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2841 DE 17-06-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.